The therapeutic effect and clinical application of mitapivat-Pyrukynd

Mitapivat (mitapivat) -Pyrukynd is a pyruvate kinase (PK) activator and is mainly used to treat hemolytic anemia caused by pyruvate kinase deficiency (PK deficiency) in adults. PK deficiency is a rare genetic disease in which patients suffer from a deficiency in pyruvate kinase, which shortens the lifespan of red blood cells and causes hemolytic anemia, manifesting as symptoms such as fatigue, paleness, jaundice, and heart palpitations.

The therapeutic effect of Metapival is mainly reflected in activating the activity of pyruvate kinase, thereby restoring normal red blood cell metabolism, slowing down the destruction of red blood cells, and improving anemia symptoms. In clinical studies, metapival significantly increased patients' hemoglobin levels and reduced hemolysis. In addition, the patient's symptoms, such as fatigue and physical discomfort, were significantly improved.

The mechanism of action of Metapival is mainly by increasing the ATP levels in red blood cells to promote the survival of red blood cells. Pyruvate kinase is one of the important enzymes in red blood cells and participates in the glycolysis process. By activating this enzyme, Metapival improves glycolysis and ensures that red blood cells can obtain sufficient energy, thereby extending their life cycle.

The clinical application of metapival is mainly aimed at adult patients with PK deficiency. Due to the lack of PK enzyme activity in these patients, their red blood cells have a shorter survival time, resulting in long-term anemia and related symptoms. The use of Metapival can significantly reduce anemia symptoms and improve patients' quality of life. In clinical practice, the use of metapival helps reduce patients' dependence on blood transfusions and improves patients' overall health.

In addition, metapival has shown good tolerability in some clinical trials, and most patients' side effects are mild and can be controlled to a certain extent. Common side effects include headache, fatigue, and mild gastrointestinal discomfort, which are usually temporary and do not affect the continuation of treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd